GlassScriptPhysician profile
Joseph E Whitfield
NPI 1265495683
$17,122.84
in general payments reported to CMS, 2019-2025
26 companies · $4,493 in 2025
The $4,493 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,071 · 2022: $2,451 · 2023: $3,729 · 2024: $4,380 · 2025: $4,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,489.49 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,462.69 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $1,793.52 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,761.71 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $1,362.58 | 2021-2025 | Azstarys, Adlarity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,285.25 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $945.52 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $929.55 | 2021-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $924.27 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $919.62 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $840.48 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $797.23 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $560.69 | 2021-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $450.14 | 2022-2025 | Cobenfy |
| Indivior INC. | $342.11 | 2021-2025 | Perseris, Sublocade |
| Collegium Pharmaceutical, INC. | $311.80 | 2025 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $309.18 | 2022-2025 | Quviviq, Quviviq |
| Tris Pharma INC | $253.67 | 2021-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Eisai INC. | $238.43 | 2021-2022 | |
| Lundbeck LLC | $229.36 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $141.85 | 2023-2025 | Auvelity |
| Acadia Pharmaceuticals INC | $117.93 | 2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $57.88 | 2021-2023 | Trintellix |
| Bausch Health US, LLC | $26.56 | 2021-2022 | |
| Sage Therapeutics, LLC | $23.25 | 2024 | |
| Almatica Pharma LLC | $22.78 | 2021 | |
| Merck Sharp & Dohme LLC | $14.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Whitfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.